488706-18-9

Basic information

• Product Name: tris(methyloxycarbonylmethyl)methane
• Synonyms: tris(methyloxycarbonylmethyl)methane
• CAS NO: 488706-18-9
• Molecular Weight: 547.651
• Mol File: 488706-18-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tris(methyloxycarbonylmethyl)methane(CAS DataBase Reference)
• NIST Chemistry Reference: tris(methyloxycarbonylmethyl)methane(488706-18-9)
• EPA Substance Registry System: tris(methyloxycarbonylmethyl)methane(488706-18-9)

Safety Data

• Hazardous Substances Data: 488706-18-9(Hazardous Substances Data)

Upstream product

• 57056-38-9 tris(methyloxycarbonylmethyl)methane 
• 2393-23-9 4-methoxy-benzylamine 

Downstream Products

• 488706-20-3 1,1,1-tris[2-(p-methoxybenzylamino)ethyl]methane 
• 959149-70-3 C₃₁H₄₁N₃O₄ 
• 959149-71-4 C₃₁H₃₉N₃O₅ 

Relevant articles and documents

NOVEL IMAGING AGENTS FOR CANCER

A novel imaging agent is described which comprises a semaphorin moiety and an imaging moiety. The novel imaging agent of the invention may be used in the diagnostic imaging of cancer and in particular, for targeting angiogenesis or metaplasia. Further aspects of the present invention presented herein include a method for the preparation of the imaging agent, a pharmaceutical composition comprising the imaging agent of the invention and a kit for the preparation of said pharmaceutical.

Diagnostic imaging agents with mmp inhibitory activity

The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.

ENZYME INHIBITOR IMAGING AGENTS

The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi’s) of the hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body.